首页> 美国卫生研究院文献>other >Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma

【2h】

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma

机译：Vemurafenib对BRAF（V600E）和BRAF野生型转移性恶性黑色素瘤的体外肿瘤激酶活性的不同抑制作用。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundTreatment of metastatic malignant melanoma patients harboring BRAF(V600E) has improved drastically after the discovery of the BRAF inhibitor, vemurafenib. However, drug resistance is a recurring problem, and prognoses are still very bad for patients harboring BRAF wild-type. Better markers for targeted therapy are therefore urgently needed.

机译：背景发现BRAF抑制剂维罗非尼后，携带BRAF（V600E）的转移性恶性黑色素瘤患者的治疗得到了显着改善。然而，耐药性是一个反复出现的问题，对于携带BRAF野生型的患者，预后仍然很差。因此，迫切需要更好的靶向治疗标记物。

著录项

期刊名称 other
作者
Andliena Tahiri; Kathrine Røe; Anne H. Ree; Rik de Wijn; Karianne Risberg; Christian Busch; Per E. Lønning; Vessela Kristensen; Jürgen Geisler;
展开▼
作者单位

展开▼
年(卷),期 -1(8),8
年度 -1
页码 e72692
总页数 12
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib‐resistant BRAF BRAF V600E V600E V600E mutation bearing metastatic melanoma cells [J] . Carpenter Evan L., Chagani Sharmeen, Nelson Dylan, Molecular Carcinogenesis . 2019,第9期

机译：线粒体复合物I抑制剂Deguelin诱导代谢重编程和敏感vemurafenib抗性BRAF BRAF V600E V600E V600E突变轴承转移性黑色瘤细胞
2. Malignant melanoma, papillary thyroid carcinoma and Erdheim–Chester disease, associated with both BRAF V600E BRAF V600E V600E and mosaic Turner syndrome [J] . Clinical and experimental dermatology . 2020,第4期

机译：恶性黑素瘤，乳头状甲状腺癌和Erdheim-Chester疾病，与BRAF V600E BRAF V600E和马赛克变型综合征有关
3. Glucocorticoid receptor antagonism overcomes resistance to BRAF inhibition in BRAF V600E -mutated metastatic melanoma [J] . José M Estrela, José A Pellicer, Elena Obrador, American Journal of Cancer Research . 2019,第12期

机译：糖皮质激素受体拮抗作用克服BRAF V600E矫正转移性黑色瘤的BRAF抑制抗性
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Development of Nanoliposomes for the Treatment of Braf V600e Mutated Parent and Vemurafenib-Resistant Melanoma [D] . Fu, Yige. 2021

机译：用于治疗BRAF V600E突变父母和vemureafenib抗性黑素瘤的纳米脂质体的研制
6. Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemoresistance and Protumoral Activity in Metastatic Melanoma [O] . Aitor Benedicto, Iera Hernandez-Unzueta, Eduardo Sanz, 2021

机译：Ocoxin增加了BRAF抑制的抗肿瘤效应降低了转移性黑色瘤中的癌症相关的成纤维细胞介导的化学血管突变和原子素活性
7. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. [O] . Andliena Tahiri, Kathrine Røe, Anne H Ree, 2013

机译：vemurafenib在BRaF（V600E）和BRaF野生型转移性恶性黑素瘤中对体外肿瘤激酶活性的差异抑制。

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma

摘要

著录项

相似文献

相关主题

期刊订阅